Under 10% of people that would benefit from obesity jabs including Wegovy have access to them, warns the World Health Organization as it publishes its first guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just access to this class of drugs.
Based on estimates, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a lifelong illness that can be treated with comprehensive and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major barriers to broad availability to the jabs that can help people shift substantial body mass, explains the organization.
GLP-1 Therapy Scarcity
Even in the present most optimistic case, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of the global need, according to the health organization.
The recommendation urges countries and companies to expand availability, by approaches including patent sharing.
A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Work
The injections imitate a body's own hormone to slow digestion, suppress the appetite and increase feelings of fullness so users eat less.
People typically begin shedding pounds within a few weeks of beginning the weekly injections.
Evidence points to people may regain a significant portion after a year of halting the medication, as their normal appetite return.
To be above a healthy weight increases your chance for experiencing medical conditions, including type 2 diabetes, heart disease, stroke, and specific cancers.
Obesity impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
